Business · 03/09/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PRELAYSUPTM and REZULINSUPTM Patent Extensions
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for patent extensions for PRELAYSUPTM and REZULINSUPTM, following a submission to the US Department of Commerce for patent extension of a human drug product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →